All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Q fever is a zoonosis caused by the intracellular, gram negative bacterium *Coxiella burnetii*. *C*. *burnetii* is an extremely infectious pathogen \[[@pntd.0005521.ref001]\]. The extremely high infectivity, the ability to withstand harsh environmental conditions, and the potential to cause severe disease in man, has deemed this organism to be considered as a biological terrorist agent. It has been listed as a Category B biological warfare agent by the Centre's of Disease Control and Prevention \[[@pntd.0005521.ref002],[@pntd.0005521.ref003]\].

*C*. *burnetii* infects people and a wide range of wild and domesticated animals. Within the environment, *C*. *burnetii* survives in arthropod hosts, such as ticks. From these hosts it can spread, and it primarily spreads into ruminants. Domestic ruminants (primarily cattle, sheep and goats) are the most important reservoir of *C*. *burnetii* in the nature. Q fever is mostly asymptomatic in livestock and animals, except in some cases, where causes abortion, stillbirth, endometritis or infertility. Infected animals shed *C*. *burnetii* into the environment in milk, colostrum, urine, vaginal discharges and especially in birth products \[[@pntd.0005521.ref004],[@pntd.0005521.ref005]\]. High numbers of organisms exist in the amniotic fluids and placenta during birthing (e.g., 10^9^ bacteria/g placenta) \[[@pntd.0005521.ref006]\]. *C*. *burnetii* can survive for long periods in the environment, and it is common for aerosols from infected herds to be carried by the wind and cause infection in humans. Q fever outbreaks could be directly connected to the speed and frequency of the wind \[[@pntd.0005521.ref007]\]. Inhalation of infectious aerosol or contaminated dusts containing air-borne bacterium the major route of acquiring the disease in humans, so that a single inhaled organism may produce clinical illness. Nevertheless, the other routes of transmission of this infection to human are consumption of contaminated milks and dairy products, skin or mucosal contact, tick bites, blood transfusion, sexual transmission and embryo transfer \[[@pntd.0005521.ref004],[@pntd.0005521.ref005],[@pntd.0005521.ref008]\].

Clinical manifestations of Q fever in humans includes acute, chronic to fatigue syndrome. The main characteristic of Q fever is its clinical polymorphism. Acute Q fever is defined as primary infection with *C*. *burnetii*, and \<60% of infected patients may be asymptomatic \[[@pntd.0005521.ref009]\]. However, acute Q fever can manifest as a flu-like and self-limited illness, and major clinical presentations of these patients are fever, headache, coughing, atypical pneumonia, hepatitis, myalgia, arthralgia, cardiac involvement, skin rash and neurologic signs, and 2% of patients with acute disease are hospitalized. The case fatality rate of acute Q fever is reported up to 1--2% \[[@pntd.0005521.ref004],[@pntd.0005521.ref008],[@pntd.0005521.ref010]\]. Approximately 5% of acute Q fever cases go on to develop chronic Q fever. People may become chronically infected without having being previously diagnosed with acute disease, and chronic Q fever may manifest months or years after an acute infection \[[@pntd.0005521.ref011]\]. Chronic Q fever is accompanied with endocarditis, vascular infection, prosthetic joint arthritis, osteoarticular infection and lymphadenitis \[[@pntd.0005521.ref004],[@pntd.0005521.ref012],[@pntd.0005521.ref013]\]. Endocarditis and vascular infection caused by Q fever are fatal if untreated\[[@pntd.0005521.ref009]\].

Human Q fever has been described in countries around the world, New Zealand being the only exception. As it is not a notifiable disease in many countries, the geographical distribution of the organism is extrapolated from serological surveys and investigated outbreaks\[[@pntd.0005521.ref003]\]. In Iran, the first clinical cases of acute Q fever are reported in 1952. From 1970 to 1976, 133 patients with acute Q fever were reported from different parts of Iran \[[@pntd.0005521.ref014]\]. After 1976, Q fever was neglected in Iran, and no human case was reported. At the same time with large outbreak of Q fever in the Netherlands (2007--2010)\[[@pntd.0005521.ref015]\],*C*. *burnetii* antibodies were reported in febrile patients in the Kerman province (southeastern Iran), \[[@pntd.0005521.ref016]\]and investigation for Q fever was resumed. After that, various seroepidemiological studies were conducted on animal and human population. The first case of chronic Q fever (endocarditis) was reported in 2013 \[[@pntd.0005521.ref017]\].

We do not have an overall estimation of Q fever infection in Iran. Current studies have reported Q fever seroprevalence in human and domestic animals. The overall estimation of Q fever seroprevalence in the human and animal population will help health policymakers create or modify control and prevention programs for Q fever in Iran. In the present systematic review, we reviewed the local Iranian publications on Q fever and also international publications relating to the disease in Iran. In this report we provide a summary of the more recent data collected on Q fever in Iran.

Methods {#sec006}
=======

Information sources and search {#sec007}
------------------------------

From January 2005 to June 2016, we searched the literature for articles that assessed the prevalence of Q fever infection in human and animals in Iran.

We searched multiple English and Persian electronic data sources including Iranmedex, Scientific Information Database (SID), Magiran, Iranian Research Institute for Information Science and Technology (IRANDOC), Google Scholar, Medline, PubMed, Science Direct, Scopus and Web of science. In addition, the citations of the included articles were reviewed to find other relevant studies. We also looked at the electronic abstract list of congress conducted in Iran and also at the electronic database of students' thesis. Keywords that we used for our search were "Q fever, *Coxiella burnetii* and Iran\".

Eligibility criteria and study selection {#sec008}
----------------------------------------

Articles with cross sectional design which were sampling from Iran, published in Persian or English and measured seroposivity by serological assays (just IgG) were eligible to enter meta-analysis.

Exclusion criteria for studies from systematic review were: 1- Lack of access to full article or insufficient data in abstract; 2- Unclear testing methods used to detect studied infection or non-serology test 3- IgM detection4- other study design except cross sectional.

We contacted the corresponding author when we have questions about the eligibility of the article.

Data collection and data items {#sec009}
------------------------------

Data was extracted by two reviewers and checked twice based on the following items: type of study, sample size, location and time of the study, species and prevalence of Q fever. We grouped the studies with species in herd and individual level as sheep, goat, cattle and camel and also human participants as phase I and phase II IgG.

Analytic approach {#sec010}
-----------------

We conducted meta-analyses in STATA version 12. We did meta-analysis for Q fever prevalence in any species in herd and individual level and in phase I and II for human. The outcome was measured and reported as prevalence, with point and 95% confidence intervals. A Q-test was used to assess heterogeneity. When the heterogeneity test had a p-value less than 0.1, a random-effects model was used; otherwise the fixed-effects model was used to calculate the pooled prevalence. Also by calculating pooled Q fever seroprevalence in each province we mapped prevalence of Q fever using ArcGIS ver. 10.2.

Results {#sec011}
=======

Description of included studies {#sec012}
-------------------------------

As presented in [Fig 1](#pntd.0005521.g001){ref-type="fig"}, we found 163 abstracts in our literature review. After removing duplications (n = 87) based on title and abstract, 76 remained for full text review. Of those, 48 articles were excluded for various reasons including non-serology test (n = 34), review article (n = 7), IgM assessing study (n = 1), publish of Q fever study of other country in Iranian journals (n = 3), other kind of study (n = 2) and no access to full text (n = 1) ([Fig 1](#pntd.0005521.g001){ref-type="fig"}). Characteristics of the final included studies (n = 28) in the systematic review showed in [Table 1](#pntd.0005521.t001){ref-type="table"}.

![Flow diagram of included and excluded records](pntd.0005521.g001){#pntd.0005521.g001}

10.1371/journal.pntd.0005521.t001

###### Characteristics of the included studies in the systematic review, 2005--2016.

![](pntd.0005521.t001){#pntd.0005521.t001g}

               Group                  Level                  Sample Size   Time Study   Province                 Reference
  ------------ ---------------------- ---------------------- ------------- ------------ ------------------------ ----------------------------
  1            Human                  Phase I                187           2011         Sistan and Baluchistan   \[[@pntd.0005521.ref044]\]
  Phase II                                                                                                       
  2            Human                  Phase I                75            2009         Kerman                   \[[@pntd.0005521.ref016]\]
  Phase II                                                                                                       
  3            Human                  Phase I                250           2011--2012   Kurdistan                \[[@pntd.0005521.ref045]\]
  Phase II                                                                                                       
  4            Human                  Phase II               200           2014         Ardabil                  \[[@pntd.0005521.ref046]\]
  Khuzestan                                                                                                      
  5            Human                  Phase II               105           2011         Sistan v Baluchistan     \[[@pntd.0005521.ref047]\]
  6            Human                  Phase II               45            2013         Kerman                   \[[@pntd.0005521.ref048]\]
  7            Human                  Phase II               75            2010--2011   Kerman                   \[[@pntd.0005521.ref049]\]
  8            Human                  Phase II               121           2014         Kerman                   \[[@pntd.0005521.ref050]\]
  9            Human                  Phase II               53            2015--2016   Mazandaran               \[[@pntd.0005521.ref051]\]
  10           Human                  Phase II               92            2014         South Khorasan           \[[@pntd.0005521.ref052]\]
  11           Sheep                  Herd                   10            2009         Kerman                   \[[@pntd.0005521.ref053]\]
  Individual   85                                                                                                
  12           Sheep                  Herd                   29            2012         Khorasan Razavi          \[[@pntd.0005521.ref054]\]
  Individual   255                                                                                               
  13           Sheep                  Herd                   10            2014         Hamadan                  \[[@pntd.0005521.ref041]\]
  Individual   200                                                                                               
  14           Sheep                  Individual             256           2011--2012   Ardabil                  \[[@pntd.0005521.ref055]\]
  15           Sheep                  Individual             235           2011--2012   Fars                     \[[@pntd.0005521.ref034]\]
  336          Isfahan                                                                                           
  297          Khorasan Razavi                                                                                   
  232          Markazi                                                                                           
  16           Sheep                  Individual             12            2011         Hormozgan                \[[@pntd.0005521.ref035]\]
  37           2011                   Kerman                                                                     
  78           2011                   Sistan v Baluchistan                                                       
  17           Sheep                  Individual             220           2010--2011   Khuzestan                \[[@pntd.0005521.ref056]\]
  18           Sheep                  Individual             253           2011--2012   Mazandaran               \[[@pntd.0005521.ref057]\]
  19           Goat                   Herd                   9             2008         Kerman                   \[[@pntd.0005521.ref058]\]
  Individual   79                                                                                                
  20           Goat                   Herd                   28            2012         Khorasan Razavi          \[[@pntd.0005521.ref054]\]
  Individual   205                                                                                               
  21           Goat                   Herd                   10            2014         Hamadan                  \[[@pntd.0005521.ref041]\]
  Individual   50                                                                                                
  22           Goat                   Individual             76            2011--2012   Fars                     \[[@pntd.0005521.ref034]\]
  76           Isfahan                                                                                           
  13           Khorasan Razavi                                                                                   
  15           Markazi                                                                                           
  23           Goat                   Individual             58            2011         Kerman                   \[[@pntd.0005521.ref059]\]
  24           Goat                   Individual             39            2011         Hormozgan                \[[@pntd.0005521.ref035]\]
  136          Kerman                                                                                            
  66           Sistan v Baluchistan                                                                              
  25           Cattle                 Herd                   10            2014         Hamedan                  \[[@pntd.0005521.ref041]\]
  Individual   120                                                                                               
  26           Cattle                 Herd                   12            2008         Kerman                   \[[@pntd.0005521.ref058]\]
  Individual   93                                                                                                
  27           Cattle                 Herd                   44            2010         Kerman                   \[[@pntd.0005521.ref060]\]
  28           Cattle                 Herd                   19            2011         Kerman                   \[[@pntd.0005521.ref040]\]
  Individual   161                                                                                               
  29           Cattle                 Herd                   19            2010         Khorasan Razavi          \[[@pntd.0005521.ref061]\]
  Individual   246                                                                                               
  30           Cattle                 Herd                   34            2014         Kurdistan                \[[@pntd.0005521.ref062]\]
  31           Cattle                 Herd                   37            2014         West Azerbaijan          \[[@pntd.0005521.ref063]\]
  32           Cattle                 Individual             86            2011         Khuzestan                \[[@pntd.0005521.ref064]\]
  33           Camel                  Individual             42            2012--2013   Khorasan Razavi          \[[@pntd.0005521.ref065]\]
  59           North Khorasan                                                                                    
  66           South Khorasan                                                                                    
  34           Dog                    Individual             182           2013--2014   Khuzestan                \[[@pntd.0005521.ref066]\]

Prevalence of seropositivity {#sec013}
----------------------------

### Q fever seroprevalence in human {#sec014}

In final, 10 studies were found about seroprevalence of Q fever in different parts of Iran which three studies were about IgG phase I antibody and eighth studies were IgG phase II antibody. The overall seroprevalence of IgG phase I and II antibodies of Q fever in human was 19.80% (95% CI: 16.35--23.25%) and 32.86% (95% CI: 23.80--41.92%), respectively ([Table 2](#pntd.0005521.t002){ref-type="table"}). Geographical distribution of Q fever seropositivity was shown in [Fig 2](#pntd.0005521.g002){ref-type="fig"}. *C*. *burnetii* antibodies have been detected in human from 9 provinces. The most prevalence of IgG phases I and II antibodies was seen in Kerman (24%) and South Khorasan (54%) provinces, respectively ([Fig 2](#pntd.0005521.g002){ref-type="fig"}).

![Geographical distribution of anti- *C*. *burnetii* IgG Phase I (A) and IgG Phase II (B) among Iranian people.](pntd.0005521.g002){#pntd.0005521.g002}

10.1371/journal.pntd.0005521.t002

###### Prevalence Q fever antibody among human and domestic animals, 2005--2016

![](pntd.0005521.t002){#pntd.0005521.t002g}

               Level        Sample size   Number of studies      Pooled estimate (%)
  ------------ ------------ ------------- ---------------------- -----------------------
  **Human**    Phase I      512           3                      19.80 (16.35--23.25)
  Phase II     1203         10            32.86 (23.80--41.92)   
  **Goat**     Herd         47            3                      93.42(80.23--100.00)
  Individual   813          6             31.97 (20.96--42.98)   
  **Sheep**    Herd         49            3                      96.07 (89.11--100.00)
  Individual   2496         9             24.66 (19.81--29.51)   
  **Cattle**   Herd         175           7                      41.37 (17.88--64.86)
  Individual   706          5             13.30 (2.98--23.62)    
  **Camel**    Individual   167           1                      28.26 (21.47--35.05)
  **Dog**      Individual   182           1                      0.55 (0.03--2.68)

### Q fever seroprevalence in goat {#sec015}

Six studies were conducted about seroprevalence of Q fever in goats which three studies were in herd level and six studies were in individual's level. The herd and individual prevalence of Q fever antibody in goat were 93.42% (95% CI: 80.23--100.00) and 31.97% (95% CI: 20.96--42.98%), respectively. The higher and lower seroprevalence was seen in Kerman (63.3%) and Markazi (0%) provinces, respectively. Also seroprevalence of Q fever among goats in Iran showed [Fig 3](#pntd.0005521.g003){ref-type="fig"}.

![Geographical distribution of Q fever seropositivity among goats in individual (A) and herd (B) levels in the Iran.](pntd.0005521.g003){#pntd.0005521.g003}

### Q fever seroprevalence in sheep {#sec016}

In final, 8 studies were found about seroprevalence of Q fever in sheep's, which 3 studies were in herd level and 9 studies were in individual's level. The herd and individual prevalence of Q fever antibody in sheep's were 96.07% (95% CI: 89.11--100.00%) and 24.66% (95% CI: 19.81--29.51%), respectively. The higher and lower seropositivity of *C*. *burnetii* among sheep's showed in Sistan va Baluchestan (43.6%) and Khorasan Razavi (12.8%) provinces, respectively. Also geographical distribution of Q fever seropositivity in sheep's was shown in [Fig 4](#pntd.0005521.g004){ref-type="fig"}.

![Geographical distribution of *C*. *burnetii* seroprevalence among sheep's in individual (A) and herd (B) levels in Iran.](pntd.0005521.g004){#pntd.0005521.g004}

### Q fever seroprevalence in cattle {#sec017}

In final, 8 studies had been done about seroprevalence of Q fever in sheep's, which 7 studies were in herd level and 5 studies were in individual's level. The herd and individual prevalence of Q fever antibody in cattle were 41.37% (95% CI: 17.88--64.86%) and 13.30% (95% CI: 2.98--23.62%), respectively. The seroprevalence of Q fever among cattle's in the different parts of Iran showed in [Fig 5](#pntd.0005521.g005){ref-type="fig"}.

![Geographical distribution of Q fever seropositivity among cattle's in individual (A) and herd (B) levels in Iran.](pntd.0005521.g005){#pntd.0005521.g005}

### Other animals {#sec018}

Only one study found the seroprevalence of dogs and camels in Iran. Individual seropositivity of Q fever in camel and dog were 28.26% (95% CI: 21.47--35.05) and 0.55% (0.03--2.68), respectively.

Discussion {#sec019}
==========

The current systematic review reports the seroprevalence of Q fever among human and domestic animals in Iran. The results of this meta-analysis showed the prevalence of IgG phase I and II antibodies of *C*. *burnetii* among human in Iran were 19.80% and 32.86%, respectively. These rates were very high compared with other similar study. As example seropositivity of Q fever in China was reported 10% \[[@pntd.0005521.ref018]\]. In a recent systematic review study, human seroprevalence was reported from 1--32% in Africa \[[@pntd.0005521.ref019]\]. Human seroprevalence of Q fever were reported 3 to 35.8% in Kenya \[[@pntd.0005521.ref020]\], 12.3--32%in Turkey\[[@pntd.0005521.ref021],[@pntd.0005521.ref022]\], 15.3% in Spain \[[@pntd.0005521.ref023]\],5.2%in Australia\[[@pntd.0005521.ref024]\]and 11% in Denmark\[[@pntd.0005521.ref025]\]. Overall seroprevalence for *C*. *burnetii* was reported 3.1% among general population in the USA \[[@pntd.0005521.ref026]\]. The differences between countries could be due to varieties in ecologic, social, cultural, behavioral and economical conditions and also levels of animals infections, which affect the exposures of people in each of the regions of the world. In all conducted studies in Iran, *C*. *burnetii* antibodies have been detected in human from 9 provinces. Seroprevalence varied in different areas of Iran. The seroprevalence of IgG phase I of Q fever ranged from 18.2% to 24%, which Sistan and Baluchestan and Kerman provinces had lowest and highest seropositivity, respectively. Also the prevalence of IgG phase II antibodies ranged from 14.5% to 68%, which higher and lower seroprevalence showed in Kerman and Sistan and Baluchestan provinces, respectively \[[@pntd.0005521.ref017],[@pntd.0005521.ref018]\]. According to the findings of this study, it is highly recommended that physicians and health care workers are informed about bacteria circulating in Iran.

Goats are important sources of *C*. *burnetii* infection in people and seven serosurveys were conducted on goats in Iran between 2005 and 2016. According to the results of this meta-analysis, the seroprevalence of Q fever in goats was 31.97%. Also, 93.42% of the goat's herds were seropositive in Iran. In similar studies, goats seropositivity were 13% to 23% in Africa \[[@pntd.0005521.ref019]\],20% to 46% in Kenya \[[@pntd.0005521.ref020]\] and 0.8% to 60.6% in China \[[@pntd.0005521.ref018]\]. Antibodies against *C*. *burnetii* in Netherland, Bulgaria and Bangladesh were 7.8%, 13.7% and 9.52%, respectively \[[@pntd.0005521.ref027]--[@pntd.0005521.ref029]\]. Our study showed *C*. *burnetii* antibodies have been detected in goats from 7 provinces. The higher and lower seroprevalence was seen in Kerman (65.8%) and Markazi (0%) provinces, respectively. From 2007 to 2010, more than 4,000 human cases were diagnosed in Netherlands. The outbreaks in humans were mainly related area with intensive dairy goat farming \[[@pntd.0005521.ref015]\]. A recent (2012--2014) human outbreak of Q fever in the Australia was linked to an intensive goat and sheep dairy farm and also seroprevalence in goats was 15% \[[@pntd.0005521.ref030]\]. Due to the recent outbreaks of Q fever, it seems that the goat is very strong role in human infections. In Iran, due to the high seroprevalence antibodies to *C*. *burnetii* in goats, this case can be possible, but more studies are needed to prove this point in the future.

Large human Q fever outbreaks related to sheep in published studies around the world included Bulgaria (2009), Croatia (2008),France (2007), Germany (2006, 2008), Italy (2004) and Switzerland (1987) \[[@pntd.0005521.ref031]\]. Therefore, sheep is considered as an important factor for human Q fever infection. The results of this meta-analysis demonstrated that were 24.66% of sheep's had antibody of *C*. *burnetii* in Iran. In total, seroprevalence of Q fever was 96.07% among sheep's herds. Different rates of sheep seroprevalence were reported in other countries, so that the seropositivity was 2.4% in Netherlands \[[@pntd.0005521.ref032]\], 5% in China \[[@pntd.0005521.ref018]\], 11.6% in Bulgaria \[[@pntd.0005521.ref028]\], 20% in Turkey \[[@pntd.0005521.ref033]\] and 11% to 33% in Africa \[[@pntd.0005521.ref019]\]. The studies of Q fever seroprevalence found in 12 provinces in Iran. The higher and lower seropositivity of *C*. *burnetii* among sheep's showed in Sistan and Baluchestan (43.6%) and Khorasan Razavi (12.8%) provinces, respectively \[[@pntd.0005521.ref034],[@pntd.0005521.ref035]\].

In cattle\'s like other main reservoirs (sheep and goat) of Q fever, *C*. *burnetii* is shed by birth products (placenta, birth fluids), but may also be shed by vaginal mucus, milk, and faeces, urine and semen\[[@pntd.0005521.ref036]\].Contact with these contaminated materials can lead to human infection. According to the results of this meta-analysis, the seroprevalence of Q fever in cattle was 13.30%. Also, 41.37% of the cattle's herds were seropositive in Iran. In other countries, seroprevalence of Q fever was different rates among cattle, for example: 6.2% in Northern Ireland\[[@pntd.0005521.ref037]\], 8.5% in in Bulgaria \[[@pntd.0005521.ref028]\], 15% in China \[[@pntd.0005521.ref018]\], 16.0% in Netherlands \[[@pntd.0005521.ref038]\] and 30.4% in Cameroon \[[@pntd.0005521.ref039]\]. In all conducted studies in Iran, *C*. *burnetii* antibodies have been detected in human from 7 provinces. The higher and lower seroprevalence of Q fever was seen in Kerman (29.2%) and Hamadan (0.8%) provinces, respectively\[[@pntd.0005521.ref040],[@pntd.0005521.ref041]\]. The lower seroprevalence in cattle's compared to the two other main reservoirs (sheep and goat) in Iran, this can be caused by difference in strains circulating in Iran and other areas and genotyping studies can be helpful in support of this subject. Therefore, it seems that there are differences in geographic prevalence of the disease among cattle in Iran and it is recommended to be done in the future a comprehensive study to determine the case in all provinces of Iran.

The seropositivity of Q fever among camel was 28.26% in Iran. Antibodies to *C*. *burnetii* were reported in 51.6% and 80% of camels in Saudi Arabia and Chad, respectively \[[@pntd.0005521.ref042],[@pntd.0005521.ref043]\]. Also, the seroprevalence of Q fever was 0.55% among dogs in Iran, but only one study conducted in Iran. For better judgment on this issue needs more studies in the future.

Although human and animal infections of Q fever are known to occur and endemic in Iran, but the Q fever is not a reportable disease in the country and clinical cases are probably largely unrecognizable by health system. There is a need for information on the epidemiology of *C*. *burnetii* in Iran as well as many other issues such as distribution, pathogenesis and molecular typing. The data from the studies to date in Iran provide only a basic picture of Q fever in the country. Active case finding and further research studies are recommended, to more clearly define the epidemiology and importance of *C*. *burnetii* infections in animals and people in Iran. This will enable the formulation and implementation of locally applicable control methods for Q fever which can be implemented by animal and human healthcare workers.
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